{"nctId":"NCT00150969","briefTitle":"Vitamin K Supplementation in Post-Menopausal Osteopenia","startDateStruct":{"date":"2002-01"},"conditions":["Post-Menopausal Osteoporosis","Post-Menopausal Osteopenia"],"count":440,"armGroups":[{"label":"phyloquinone","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: vitamin K1 (phylloquinone)"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: placebo"]}],"interventions":[{"name":"vitamin K1 (phylloquinone)","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPostmenopausal: One year since the natural cessation of menses, or Hysterectomy with either postmenopausal status confirmed by FSH lab values, or age 55 and above AND 2. Osteopenic: T-score at baseline has to be between (and including) -1.0 and\n\n-2.0 in the lumbar spine (L1-L4), total hip or femoral neck, and the lowest reading of the above three measurements must be between -1.0 and -2.0\n\nExclusion Criteria:\n\n1. Women ever having had a fragility fracture after age 40;\n2. Women currently on anticoagulants, previously on anticoagulants in the past 3 months, or expected to be on anticoagulants in the near future;\n3. Women on hormone replacement therapy, raloxifene, bisphosphonates or calcitonin during the past 3 months;\n4. Women who have ever been on a bisphosphonate for more than 6 months;\n5. Women previously diagnosed with Paget's disease, hyperparathyroidism, hyperthyroidism or other metabolic bone diseases;\n6. Women with decompensated diseases of the liver, kidney, pancreas, lung, or heart;\n7. Women with a history of active cancer in the past 5 years;\n8. Women taking mega-doses of vitamin A (more than 10,000 iu per day) or E (more than 400 iu per day);\n9. Women involved in other clinical trials;\n10. Any women who, in the opinion of the principal investigator, is at poor medical or psychiatric risk for the study.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"3.5"},{"groupId":"OG001","value":"-1.22","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"3.7"},{"groupId":"OG001","value":"-1.83","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.49","spread":"4.0"},{"groupId":"OG001","value":"-2.55","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker","description":"measured by osteocalcin on elecsys platform","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"7.3"},{"groupId":"OG001","value":"24","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)","description":"measured by CTX Elisa assay on elecsys platform","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.21"},{"groupId":"OG001","value":"0.54","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin","description":"measured by osteocalcin hydroxyapatite binding assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.4","spread":"10.3"},{"groupId":"OG001","value":"-2.0","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"3.6"},{"groupId":"OG001","value":"-1.52","spread":"4.5"}]}]}]},{"type":"PRIMARY","title":"Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"2.8"},{"groupId":"OG001","value":"-0.88","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"4.7"},{"groupId":"OG001","value":"-1.76","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.05","spread":"4.3"},{"groupId":"OG001","value":"-2.71","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.","description":"BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.35","spread":"5.1"},{"groupId":"OG001","value":"-5.23","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Difference in Serious Adverse Events","description":"These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Number of New Cancers by Treatment Arm.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Number of New Clinical Fractures by Treatment Arm.","description":"these included fragility fractures","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":217},"commonTop":["nausea and vomitting"]}}}